Loading...
•
Mar 31, 2025
Medifast Q1 2025 Earnings Report
Reported results for the first quarter ended March 31, 2025
Key Takeaways
Medifast reported a significant decrease in revenue and a net loss for the first quarter of 2025, primarily driven by a decrease in the number of active earning OPTAVIA coaches. Despite the challenges, the company maintains a strong balance sheet with substantial cash reserves and no debt.
Revenue decreased 33.8% to $115.7 million in Q1 2025 compared to Q1 2024.
The company reported a net loss of $0.8 million, or $0.07 per share, in Q1 2025.
The number of active earning OPTAVIA coaches decreased 32.8% to 25,400.
Medifast ended the quarter with $164.6 million in cash, cash equivalents, and investment securities and no debt.
Forward Guidance
For the second quarter of 2025, the company expects revenue to be in the range of $85 million to $105 million and loss per share to be between $0.00 and $0.55, excluding gains or losses from the LifeMD investment.
Positive Outlook
- Focus on revitalizing coach and customer base.
- Supporting coaches with enhanced tools, data, and new products.
- Business focus remains on reestablishing sustainable long-term growth.
- Aiming to improve profitability.
- Maintaining a strong balance sheet with no debt.
Challenges Ahead
- Expected decrease in second quarter revenue compared to Q1 2025.
- Anticipated loss per share in the second quarter.
- Continued challenges in customer acquisition.
- Lower year-over-year declines in revenue per active earning coach, indicating ongoing pressure.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...